Page 1 of 32 Accepted Preprint first posted on 29 October 2012 as Manuscript EJE-12-0655 1 1 2 Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome 3 4 Dimitrios Panidis 1, Konstantinos Tziomalos 2, Panagiotis Chatzis 1, Efstathios 5 Papadakis 1, Dimitrios Delkos 1, Elena A. Tsourdi 1, Eleni A. Kandaraki 1, Ilias Katsikis 1 6 7 8 9 10 1 Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece, 2 First Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece 11 12 13 14 15 16 17 18 Corresponding author: Konstantinos Tziomalos, MD, PhD First Propedeutic Department of Internal Medicine, AHEPA Hospital 1 Stilponos Kyriakidi street, 546 36, Thessaloniki, Greece Tel. +30 2310994621 Fax. + 30 2310274434 e-mail: ktziomalos@yahoo.com 19 20 21 22 23 Short title: Cycle irregularities in PCOS Keywords: polycystic ovary syndrome, insulin resistance, amenorrhea, oligomenorrhea, polymenorrhea Text word count: 2,353 24 Copyright 2012 European Society of Endocrinology.
Page 2 of 32 2 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 Abstract Objective: Insulin resistance (IR) is frequent in polycystic ovary syndrome (PCOS) and contributes to the increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) of this population. Several markers of IR are used but most are expensive or have limited sensitivity and specificity. Preliminary data suggest that the menstrual cycle pattern correlates with IR in PCOS but existing studies are small. We aimed to assess the relationship between the type of menstrual cycle irregularities and IR in PCOS. Design: Prospective study. Methods: We studied 1,285 women with PCOS, divided according to the menstrual cycle pattern. Results: Patients with isolated secondary amenorrhea and those with secondary amenorrhea alternating with regular menstrual cycles were more insulin resistant than patients with regular cycles (Group D). Patients with isolated oligomenorrhea were also more insulin resistant than Group D. However, patients with oligomenorrhea alternating with regular cycles, secondary amenorrhea or polymenorrhea had comparable levels of markers of IR with Group D. Moreover, patients with oligomenorrhea alternating with regular cycles were less insulin resistant than patients with secondary amenorrhea alternating with regular cycles. Finally, patients with isolated polymenorrhea and those with polymenorrhea alternating with regular cycles had comparable levels of markers of IR with Group D. Conclusions: Amenorrhea is associated with more pronounced IR in PCOS, oligomenorrhea portends a less excessive risk for IR than amenorrhea whereas polymenorrhea appears to be even more benign metabolically. Therefore, the type of menstrual cycle abnormality appears to represent a useful tool for indentifying a more adverse metabolic profile in PCOS. 49
Page 3 of 32 3 50 51 Keywords: polycystic ovary syndrome, insulin resistance, amenorrhea, oligomenorrhea, polymenorrhea 52
Page 4 of 32 4 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 Introduction The polycystic ovary syndrome (PCOS) is a frequent endocrine disorder with considerable heterogeneity in its manifestations [1,2]. A substantial proportion of patients with PCOS have insulin resistance (IR), which results in increased risk for impaired glucose tolerance and type 2 diabetes mellitus (T2DM) [1-4]. Accumulating data suggest a higher incidence of cardiovascular disease (CVD) in this syndrome and IR appears to contribute to this increased risk [5,6]. Given the frequent presence of IR in patients with PCOS and its association with adverse consequences (T2DM and CVD), it is important to identify patients with PCOS who are insulin resistant. Obesity is a major risk factor for IR both in the general population and in patients with PCOS [2,7]. However, IR can be present even in normal weight patients with PCOS [8]. Oligo- and anovulation is a pivotal characteristic of PCOS and also appears to correlate with the presence of IR [1,2]. However, assessment of ovulation requires laboratory investigations and is costly. On the other hand, menstrual cycle irregularity is a relatively accurate surrogate of ovulation and is easily obtained from the medical history [1,9]. Therefore, menstrual cycle pattern might serve as a marker of IR in patients with PCOS, since IR can induce oligo- or anovulation and thus menstrual cycle irregularity by exacerbating hyperandrogenemia and by disrupting follicular growth [2]. Nevertheless, there very few small studies evaluated the association between menstruation abnormalities and the endocrine and metabolic characteristics in PCOS [10-13]. We aimed to assess the relationship between menstrual cycle irregularities and both IR and circulating androgens in a large cohort of patients with PCOS. We also aimed to determine whether different types of menstruation abnormalities are associated with more pronounced IR and hyperandrogenemia in this population.
Page 5 of 32 5 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 Patients and methods Patients We studied 1285 women with PCOS [mean age 24.3±5.8 years, mean body mass index (BMI) 26.7±6.9 kg/m 2 ] who were outpatients at the Gynecological Endocrinology Infirmary of the Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki. Diagnosis of PCOS was based on the revised criteria of Rotterdam [14]. None of the women studied had galactorrhea or any endocrine or systemic disease that could possibly affect reproductive physiology. A Synachten test was performed with tetracosactide (Synachten 0.25 mg/1ml; Novartis Pharma, Rueil-Malmaison, France) in women with a basal 17α-hydroxyprogesterone (17α-OHP) plasma level >1.5 ng/ml to exclude congenital adrenal hyperplasia. No woman reported use of any medication that could interfere with the normal function of the hypothalamic-pituitary-gonadal axis during the last semester. Informed consent was obtained from all women, and the study was approved by the Institutional Review Board; the study met the requirements of the 1975 Helsinki guidelines. Study protocol In all women, weight, height, waist circumference (W) and hip circumference (H) were measured. Body weight was measured with an analog scale and in light clothing; height was measured barefoot with a stadiometer. Body mass index (BMI) was calculated by dividing weight (in kg) by height squared (in m) to assess obesity. The W was obtained as the smallest circumference at the level of the umbilicus and the H was measured at the level of the widest diameter around the buttocks. The W to H ratio (WHR) was calculated by dividing W by H.
Page 6 of 32 6 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 Baseline blood samples were collected between days 3 and 7 of the menstrual cycle in women with regular menstrual cycles and after a spontaneous bleeding episode in women with menstrual cycle abnormalities, after an overnight fast. The circulating levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), total testosterone (T), 4 -androstenedione ( 4 -A), dehydroepiandrosterone-sulfate (DHEA-S), 17α-OHP, sex hormone-binding globulin (SHBG), glucose and insulin were measured. Immediately after baseline blood sampling an oral glucose tolerance test (OGTT) was performed; 75 g of glucose were administered orally and serum glucose levels were determined after 30, 60, 90 and 120 min. At the same day transvaginal ultrasonography was performed and the volume of each ovary was determined, as well as the number of small follicles (measuring 2-9 mm in diameter) in each ovary. Women with PCOS were divided according to the menstrual cycle pattern into: a) women with a single cycle irregularity [i.e. with primary amenorrhea (n = 4), secondary amenorrhea (n = 37), oligomenorrhea (n = 95), or polymenorrhea (n = 9)](group A), b) women with multiple cycle irregularities [i.e. with secondary amenorrhea alternating with oligomenorrhea (n = 82) or polymenorrhea (n = 23) and women with oligomenorrhea alternating with polymenorrhea (n = 147)](group B), c) women with regular menstrual cycles alternating with a single cycle irregularity [i.e. with secondary amenorrhea (n = 106), oligomenorrhea (n = 598), or polymenorrhea (n = 53)](group C), and, d) women with regular menstrual cycles (n = 131)(group D)(Figure 1). Menstrual cycle data were obtained from a diary that women were keeping for one year before enrollment to the study. For the previous years, menstrual cycle data were provided from women from memory. Primary amenorrhea was defined as the absence of menstruation by the age of 16 years. Secondary amenorrhea
Page 7 of 32 7 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 was defined as absence of vaginal bleeding for at least six months after a period of established menstruation. Oligomenorrhea was defined as cycle length > 35 days, or < 8 cycles/year. Polymenorrhea was defined as cycle length 21 days. Regular menstrual cycles were defined as cycle length 28±4 days [15]. Methods Serum FSH, LH, PRL, androgen, 17α-OHP, SHBG, glucose, insulin, TSH and FT4 were measured as previously described [16]. Free androgen index (FAI) was determined as follows: FAI = T (nmol/l) x 100 / SHBG (nmol/l) [17]. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as follows: HOMA-IR = fasting insulin (µiu/ml) x fasting glucose (mg/dl) / 405 [18]. The Quantitative insulin sensitivity check index (QUICKI) was calculated according to the following formula: QUICKI = 1 / [loginsulin (µiu/ml) + logglucose (mg/dl)] [19]. Transvaginal ultrasonography Transvaginal ultrasound scans of the ovaries were performed by an experienced sonographer in women who participated in the study. Ovarian volume was calculated by the formula: V = (π/6) x D length x D width x D thickness, where D is dimension. The presence of polycystic ovaries was diagnosed by the presence of 12 or more follicles in each ovary measuring 2-9 mm in diameter and/or increased ovarian volume (>10 cm 3 ). Statistical analysis Data analysis was performed with the statistical package SPSS (version 17.0; SPSS Inc., Chicago, IL). Data are reported as mean±sd. Differences between groups were assessed with one-way analysis of variance with the Holm-Sidak method for multiple comparison testing. Correction for age, BMI and W was carried out using
Page 8 of 32 8 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 analysis of covariance in comparisons among groups with differences in these parameters. Multiple regression analysis was performed to identify independent predictors of IR (assessed with the HOMA-IR) including in the analysis the BMI, the WHR, the menstrual pattern and circulating androgens (assessed with the FAI). In all cases, a p value <0.05 was considered significant. Results Characteristics of women with primary amenorrhea are shown in Table 1. These women (n = 4) did not differ in circulating androgens from Group D (n = 131) except for FAI, which was higher in women with primary amenorrhea (p = 0.026). In addition, women with primary amenorrhea were more insulin resistant than Group D. Characteristics of women with isolated secondary amenorrhea (n = 37) are shown in Table 1. These women did not differ in circulating androgens from Group D except for FAI and serum DHEA-S levels, which were higher in women with isolated secondary amenorrhea (p < 0.001 and p = 0.006, respectively). In addition, women with isolated secondary amenorrhea were more insulin resistant than Group D. Characteristics of women with secondary amenorrhea alternating with regular menstrual cycles (n = 106) are shown in Table 2. These women had higher circulating androgens and were more insulin resistant than Group D. Characteristics of women with isolated oligomenorrhea (n = 95) are shown in Table 1. These women did not differ in circulating androgens from Group D except for FAI, which was higher in women with isolated oligomenorrhea (p = 0.009). In addition, women with isolated oligomenorrhea were more insulin resistant than Group D. In contrast, women with oligomenorrhea alternating with regular menstrual cycles, secondary amenorrhea or polymenorrhea had comparable levels of circulating androgens and markers of IR with Group D (Tables 2 and 3). On the other hand,
Page 9 of 32 9 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 women with oligomenorrhea alternating with regular menstrual cycles had lower circulating androgens and were less insulin resistant than women with secondary amenorrhea alternating with regular menstrual cycles (Table 2). Characteristics of women with isolated polymenorrhea (n = 9) are shown in Table 1. These women did not differ in circulating androgens or markers of IR from Group D. Similarly, women with polymenorrhea alternating with regular menstrual cycles had comparable levels of circulating androgens and markers of IR with Group D (Table 2). In contrast, women with polymenorrhea alternating with regular menstrual cycles had lower circulating androgens than women with secondary amenorrhea alternating with regular menstrual cycles. In addition, women with polymenorrhea alternating with regular menstrual cycles were less insulin resistant than women with regular menstrual cycles alternating with either secondary amenorrhea or oligomenorrhea. Finally, women with polymenorrhea alternating with oligomenorrhea had lower FAI than women with secondary amenorrhea alternating with either polymenorrhea or oligomenorrhea (p = 0.003 and p = 0.006, respectively) whereas markers of IR were comparable (Table 3). In multiple regression analysis, independent predictors of HOMA-IR were the BMI (p < 0.001), the FAI (p = 0.028) and the menstrual pattern (p < 0.001). In posthoc analysis, among the different types of menstrual pattern, only primary amenorrhea, isolated secondary amenorrhea, isolated oligomenorrhea, and secondary amenorrhea alternating with oligomenorrhea were independent predictors of HOMA- IR compared with Group D (p < 0.001, p = 0.004, p = 0.004 and p = 0.037, respectively). Discussion
Page 10 of 32 10 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 This is the largest study that evaluated the association between menstrual cycle pattern and IR/androgen levels in patients with PCOS. We report that patients with isolated primary amenorrhea, secondary amenorrhea or oligomenorrhea and patients with secondary amenorrhea alternating with regular menstrual cycles had more pronounced IR than Group D. In contrast, patients with oligomenorrhea alternating with secondary amenorrhea or with regular menstrual cycles did not differ in markers of IR from Group D. Two previous smaller studies (n = 72 and 418, respectively) reported that patients with PCOS and oligomenorrhea or amenorrhea had more severe IR than patients with PCOS and regular cycles [10,11]. However, the latter studies did not differentiate between patients with oligomenorrhea and amenorrhea [10,11]. In contrast, in two more recent small studies (n = 184 and 118, respectively) that analyzed patients with amenorrhea separately from patients with oligomenorrhea, only the former had more pronounced IR than patients with regular menses [12,13]. Markers of IR did not differ between patients with oligomenorrhea and patients with regular menses [12,13]. We also observed that women with regular menstrual cycles alternating with secondary amenorrhea were more insulin resistant than women with regular menstrual cycles alternating with oligomenorrhea. There are no studies that compared markers of IR between different types of menstrual abnormalities in patients with PCOS. Overall, our findings suggest that amenorrhea is a useful marker of IR in patients with PCOS whereas oligomenorrhea does not imply more severe IR. This association is possibly explained by the relationship between IR and anovulation. Indeed, most patients with PCOS and amenorrhea are anovulatory and IR contributes to the pathogenesis of anovulation in PCOS by aggravating hyperandrogenemia and by inducing ovarian follicular arrest [1,2]. Therefore, the more severe IR might partly explain the presence of amenorrhea in these patients. On the other hand, patients with
Page 11 of 32 11 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 oligomenorrhea might have less perturbed ovulation partly because they have less severe IR. Interestingly, a recent study showed that the hormonal/metabolic profile is comparable in women with PCOS despite the time of menstrual irregularities occurrence [20]. This observation and our findings in the present study suggest that the type of menstrual irregularity might be more important than the duration of PCOS in determining the metabolic profile of these women. This is the first study that assessed the association between polymenorrhea and the metabolic and endocrine characteristics of patients with PCOS. We observed that patients with polymenorrhea alone or in combination with other cycle abnormalities or alternating with regular menstrual cycles did not differ in markers of IR from Group D. Moreover, patients with regular menstrual cycles alternating with polymenorrhea were less insulin resistant than patients with regular menstrual cycles alternating with either secondary amenorrhea or oligomenorrhea. These results suggest that polymenorrhea is associated will milder impairment in glucose metabolism than amenorrhea and oligomenorrhea. Indeed, in the general population, women with oligomenorrhea appear to have increased risk for T2DM whereas those with polymenorrhea have an incidence of T2DM similar to women with regular menses [20]. However, when clinical signs of hyperandrogenemia (hirsutism and/or acne) were present in women with polymenorrhea, the risk of T2DM increased [21]. Clearly, more studies are required to confirm or refute the relationship between polymenorrhea and IR/T2DM and to clarify the mechanism(s) underpinning this association. Differences in circulating androgens paralleled differences in markers of IR. Indeed, patients with primary or secondary amenorrhea or oligomenorrhea had more severe hyperandrogenemia than Group D whereas patients with polymenorrhea had a
Page 12 of 32 12 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 similar degree of hyperandrogenemia with the latter. A previous study reported higher androgen levels in patients with either amenorrhea or oligomenorrhea than in those with normal cycles [13] whereas another did not detect any differences in androgen levels between the three groups, possibly because of limited statistical power [12]. Therefore, it appears that the severity of menstrual abnormality also reflects the degree of hyperandrogenemia. Indeed, ovarian hyperandrogenism is associated with anovulation in PCOS by inducing ovarian follicular arrest [2,22]. Accordingly, the type of menstrual cycle irregularity might also represent an inexpensive and easily determined marker of hyperandrogenemia in patients with PCOS. In conclusion, amenorrhea is associated with more pronounced IR and hyperandrogenemia in patients with PCOS. Oligomenorrhea portends a less excessive risk for these abnormalities than amenorrhea whereas polymenorrhea appears to be even more benign metabolically. Therefore, the type of menstrual cycle abnormality might represent a useful tool for indentifying a more severe metabolic profile in PCOS. 266
Page 13 of 32 13 267 268 269 Declaration of interest There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. 270
Page 14 of 32 14 271 272 273 Funding This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. 274 275
Page 15 of 32 15 276 References 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007 370 685-697. 2. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology 2011 7 219-231. 3. Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8- year follow-up. Current Diabetes Reports 2006 6 77-83. 4. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2010 16 347-363. 5. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 1276-1284. 6. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen
Page 16 of 32 16 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. 7. Iozzo P. Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care 2009 32 Suppl 2 S168-173. 8. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 1165-1174. 9. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertility and Sterility 1998 70 274-278. 10. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, Johnston DG, Franks S. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clinical Endocrinology (Oxford) 1993 39 351-355. 11. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, Ingadottir G, Crowley WF. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. Journal of Clinical Endocrinology and Metabolism 2006 91 4842-4848. 12. Cupisti S, Kajaia N, Dittrich R, Duezenli H, W Beckmann M, Mueller A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. European Journal of Endocrinology 2008 158 711-719.
Page 17 of 32 17 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 13. Strowitzki T, Capp E, von Eye Corleta H. The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients. European Journal of Obstetrics Gynecology and Reproductive Biology 2010 149 178-181. 14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004 81 19-25. 15. De Cherney AH, Nathan L, Murphy Goodwin T, Laufer N. Current Diagnosis and Treatment Obstetrics & Gynecology, edn 10. Columbus: The McGraw-Hill Companies, 2006. 16. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti- Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. American Journal of Physiology Endocrinology and Metabolism 2009 296 E238-243. 17. Carter GD, Holland SM, Alaghband-Zadeh J, Rayman G, Dorrington-Ward P, Wise PH. Investigation of hirsutism: testosterone is not enough. Annals of Clinical Biochemistry 1983 20 262-263. 18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. 19. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for
Page 18 of 32 18 349 350 351 352 353 354 355 356 357 358 359 360 361 assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism 2000 85 2402-2410. 20. Livadas S, Christou M, Economou F, Karachalios A, Xyrafis X, Boutzios G, Zerva A, Tantalaki E, Palimeri S, Diamanti-Kandarakis E. "Menstrual irregularities in PCOS. Does it matter when it starts?". Experimental and Clinical Endocrinology & Diabetes 2011 119 334-337. 21. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. Journal of the American Medical Association 2001 286 2421-2426. 22. Agarwal SK, Judd HL, Magoffin DA. A mechanism for the suppression of estrogen production in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1996 81 3686-3691. 362
Page 19 of 32 19 363 364 365 366 367 368 369 370 Table legends Table 1. Characteristics of women with PCOS and a single cycle irregularity and of women with PCOS and regular menstrual cycles. Table 2. Characteristics of women with PCOS and a single cycle irregularity alternating with regular menstrual cycles and of women with PCOS and regular menstrual cycles. Table 3. Characteristics of women with PCOS and multiple cycle irregularities and of women with PCOS and regular menstrual cycles. 371 372 373 Figure legends Figure 1. Distribution of menstrual cycle pattern in the study population.
Page 20 of 32 Table 1. Characteristics of women with PCOS and a single cycle irregularity and of women with PCOS and regular menstrual cycles. Primary Secondary Oligo- Poly- Regular p p amenorrhea amenorrhea menorrhea menorrhea menstrual (overall) (post-hoc tests between patients with different (n=4) (n=37) (n=95) (n=9) cycles types of menstrual cycle irregularities) (n=131) PA vs. PA vs. PA vs. SA SA Oligo SA Oligo Poly vs. vs. vs. Oligo Poly Poly Age NS NS NS NS NS NS (years) 17.4±0.7 22.0±6.4 d 23.7±6.5 22.6±7.8 25.7±5.7 0.001 BMI NA NA NA NA NA NA (kg/m 2 ) 26.4±9.4 28.1±7.3 27.7±8.3 28.7±10.1 26.6±5.6 NS Waist NA NA NA NA NA NA (cm) 83.4±31.9 86.9±16.4 85.3±17.7 91.6±19.1 82.0±11.8 NS W/H 0.79±0.16 0.97±1.04 0.79±0.07 0.81±0.07 0.77±0.06 NS NA NA NA NA NA NA
Page 21 of 32 FSH 0.002 0.001 0.013 NS NS NS (IU/l) 9.1±5.2 a 5.6±1.9 5.5±1.5 c 5.6±1.2 6.2±1.7 <0.001 LH <0.001 <0.001 0.002 NS NS NS (IU/l) 22.9±25.9 a 8.8±5.7 d 7.6±5.6 10.3±6.9 d 6.1±3.9 <0.001 Prolactin NS NS NS NS 0.034 NS (ng/ml) 11.8±9.9 12.1±5.8 c 12.7±5.9 c 17.1±11.4 14.7±6.9 0.006 T NA NA NA NA NA NA (nmol/l) 77.5±37.9 83.6±30.8 79.5±34.1 72.9±20.7 73.6±27.3 NS 4 -A NA NA NA NA NA NA (nmol/l) 2.4±0.4 2.7±0.7 2.9±1.3 2.9±1.4 2.8±1.1 NS DHEA- 2795.4 2554.1 2901.3 2480.2 3158.3 NS NS NS NS NS NS S (µg/l) ±631.2 ±986.1 c ±1343.9 ±1272.6 ±1319.9 0.047 FAI 16.58±9.53 d 13.66±9.69 a 10.26±8.9 c 8.93±3.85 7.52±4.37 <0.001 NS NS NS NS NS NS 17α- 1.1±0.1 1.1±0.4 1.1±0.5 1.2±0.5 1.1±0.6 NS NA NA NA NA NA NA
Page 22 of 32 OHP (nmol/l) SHBG NA NA NA NA NA NA (nmol/l) 18.9±8.2 30.5±19.8 42.0±37.5 34.9±19.2 42.7±23.6 NS Glucose NA NA NA NA NA NA (mmol/l) 86.2±18.64 97.5±14.2 97.9±29.2 106.2±17.3 96.5±11.5 NS Insulin <0.001 <0.001 <0.001 NS NS NS (pmol/l) 54.3±70.54 a 17.7±17.3 b 14.2±8.9 d 20.2±18.3 10.4±6.4 <0.001 Glucose NS NS NS NS NS NS /insulin 3.54±2.09 d 9.30±6.35 d 9.62±6.52 b 7.32±3.15 12.57±7.65 0.002 AUC 17100.0 16415.3 15266.3 16893.7 15029.4 NA NA NA NA NA NA OGTT ±2869.9 ±4290.3 ±2891.9 ±4168.3 ±2577.6 NS HOMA- 0.010 0.002 NS NS NS NS IR 11.55±14.75 a 4.49±5.04 d 3.77±4.79 d 5.90±6.61 2.52±1.64 <0.001
Page 23 of 32 QUICKI 0.29±0.04 c 0.33±0.03 c 0.33±0.03 b 0.31±0.03 0.34±0.03 <0.001 NS NS NS NS NS NS Ovarian NA NA NA NA NA NA volume (cm 3 ) 5.9±3.5 9.6±5.1 8.5±4.6 7.7±7.8 8.1±3.4 NS Ovarian NA NA NA NA NA NA follicles 7.2±3.8 14.3±7.7 12.7±7.5 11.7±6.6 11.8±3.9 NS PA, primary amenorrhea; Oligo, oligomenorrhea; SA, secondary amenorrhea; Poly, polymenorrhea; NS, not significant; NA, not applicable; BMI, body mass index; W/H, waist to hip ratio; FSH, follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; 4 -A, 4 - androstenedione; DHEA-S, dehydroepiandrosterone sulfate; FAI, free androgen index; 17α-OHP, 17α-hydroxyprogesterone; SHBG, sex hormone-binding globulin; AUC OGTT, area under the oral glucose tolerance test curve; HOMA-IR, homeostasis model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index. Significant differences in the post-hoc comparisons between patients with regular and irregular cycles: a, p<0.001; b, p<0.005; c, p<0.01; d, p<0.05
Page 24 of 32 Table 2. Characteristics of women with PCOS and a single cycle irregularity alternating with regular menstrual cycles and of women with PCOS and regular menstrual cycles. Regular Regular Regular Regular p p menstrual cycles menstrual cycles menstrual cycles menstrual (overall) (post-hoc tests between patients with + secondary + + polymenorrhea cycles different types of menstrual cycle amenorrhea oligomenorrhea (n=53) (n=131) irregularities) (n=106) (n=598) RMC+SA RMC+SA RMC+Oligo vs. vs. vs. RMC+Oligo RMC+Poly RMC+Poly Age NS 0.005 NS (years) 23.2±5.3 b 24.4±5.6 26.4±6.5 25.7±5.7 0.001 BMI NS 0.003 0.022 (kg/m 2 ) 27.9±7.9 26.8±6.8 23.9±5.1 26.6±5.6 0.006 Waist 86.9±18.3 83.6±15.0 78.9±12.3 82.0±11.8 0.016 NS 0.016 NS
Page 25 of 32 (cm) W/H 0.79±0.07 0.78±0.07 0.77±0.07 0.77±0.06 NS NA NA NA FSH NA NA NA (IU/l) 5.8±1.8 5.9±1.8 6.5±1.9 6.2±1.7 NS LH (IU/l) 8.2±4.9 b 7.5±5.1 b 7.5±5.0 6.1±3.9 0.004 NS NS NS Prolactin NA NA NA (ng/ml) 13.6±7.2 14.5±7.5 14.6±8.3 14.7±6.9 NS T (nmol/l) 83.6±34.7 d 72.5±29.6 68.1±30.9 73.6±27.3 0.009 0.001 0.007 NS 4 -A 0.002 0.002 NS (nmol/l) 3.1±1.1 d 2.7±1.1 2.5±0.9 2.8±1.1 0.001 DHEA-S NA NA NA (µg/l) 2968.7±1344.1 2909.2±1257.2 2843.0±1237.6 3158.3±1319.9 NS FAI 11.23±7.68 b 8.36±7.05 6.65±7.69 7.52±4.37 0.007 0.001 0.023 NS 17α-OHP 1.1±0.5 1.1±0.5 1.0±0.5 1.1±0.6 NS NA NA NA
Page 26 of 32 (nmol/l) SHBG NA NA NA (nmol/l) 33.9±18.0 42.0±24.1 51.3±24.4 42.7±23.6 NS Glucose NA NA NA (mmol/l) 95.2±13.5 96.9±12.1 96.7±10.9 96.5±11.5 NS Insulin 0.001 0.020 NS (pmol/l) 16.6±22.4 a 12.0±8.4 9.9±8.6 10.4±6.4 0.002 Glucose /insulin 10.27±8.08 11.61±7.64 15.24±12.05 12.57±7.65 0.013 NS 0.015 0.019 NA NA NA OGTT 15290.4±3270.3 15461.7±3398.1 14293.4±3153.2 15029.4±2577.6 NS AUCgluc- HOMA- 0.003 0.023 NS IR 3.99±5.51 b 2.94±2.21 2.38±2.17 2.52±1.64 0.006 QUICKI 0.33±0.04 0.34±0.03 0.35±0.03 0.34±0.03 NS NA NA NA
Page 27 of 32 Ovarian NA NA NA volume (cm 3 ) 8.3±4.5 7.6±3.2 7.2±3.2 8.1±3.4 NS Ovarian NS <0.001 0.001 follicles 11.9±4.7 10.8±4.9 b 8.3±3.0 a 11.8±3.9 <0.001 RMC, regular menstrual cycles; Oligo, oligomenorrhea; SA, secondary amenorrhea; Poly, polymenorrhea; NS, not significant; NA, not applicable. Other abbreviations are defined in Table 1. Significant differences in the post-hoc comparisons between patients with regular and irregular cycles: a, p<0.001; b, p<0.005; c, p<0.01; d, p<0.05
Page 28 of 32 Table 3. Characteristics of women with PCOS and multiple cycle irregularities and of women with PCOS and regular menstrual cycles. Secondary Secondary Regular p p amenorrhea amenorrhea Oligomenorrhea menstrual cycles (overall) (post-hoc tests between patients with + + + (n=131) different types of menstrual cycle oligomenorrhea polymenorrhea polymenorrhea irregularities) (n=82) (n=23) (n=147) SA+Oligo SA+Oligo SA+Poly vs. vs. vs. SA+Poly Oligo+Poly Oligo+Poly Age (years) 23.6±5.7 d 23.6±4.4 23.8±5.6 d 25.7±5.7 0.011 NS NS NS BMI NS NA NA NA (kg/m 2 ) 26.8±7.0 25.6±6.9 25.9±7.3 26.6±5.6 Waist (cm) 83.9±16.9 82.6±15.1 82.1±15.9 82.0±11.8 NS NA NA NA W/H 0.78±0.08 0.78±0.05 0.78±0.06 0.77±0.06 NS NA NA NA FSH (IU/l) 5.5±1.7 c 6.1±1.8 5.8±1.8 6.2±1.7 0.035 NS NS NS
Page 29 of 32 LH (IU/l) 8.8±5.2 b 11.8±10.7 a 8.1±5.4 b 6.1±3.9 <0.001 NS NS 0.012 Prolactin 0.003 0.005 0.016 NS (ng/ml) 11.9±6.3 b 16.4±7.7 14.1±7.1 14.7±6.9 T (nmol/l) 74.6±33.1 89.2±42.2 71.9±28.6 73.6±27.3 NS NA NA NA 4 -A NS NA NA NA (nmol/l) 3.0±1.4 2.9±1.3 2.7±0.9 2.8±1.1 DHEA-S 0.017 0.011 NS NS (µg/l) 2890.8±1200.5 3666.2±1838.7 2907.8±1219.2 3158.3±1319.9 FAI 9.36±8.21 11.25±8.78 c 6.77±4.30 7.52±4.37 <0.001 NS 0.006 0.003 17α-OHP NS NA NA NA (nmol/l) 1.2±0.5 1.2±0.4 1.1±0.6 1.1±0.6 SHBG NS NA NA NA (nmol/l) 41.3±25.3 44.9±46.0 46.9±25.6 42.7±23.6 Glucose 96.9±11.8 95.6±11.4 98.6±11.1 96.5±11.5 NS NA NA NA
Page 30 of 32 (mmol/l) Insulin NS NA NA NA (pmol/l) 13.8±13.0 13.7±22.6 11.4±7.8 10.4±6.4 Glucose NS NA NA NA /insulin 12.41±8.26 13.32±6.99 11.77±6.28 12.57±7.65 AUCgluc- NS NA NA NA OGTT 15105.2±3097.1 16118.2±3657.3 15465.5±3140.3 15029.4±2577.6 HOMA-IR 3.37±3.21 3.19±5.15 2.82±1.98 2.52±1.64 NS NA NA NA QUICKI 0.34±0.03 0.35±0.03 0.34±0.03 0.34±0.03 NS NA NA NA Ovarian 0.014 NS NS NS volume (cm 3 ) 9.9±4.3 c 8.7±4.4 9.5±5.7 c 8.1±3.4 Ovarian NS NA NA NA follicles 12.4±4.7 10.9±3.5 12.4±8.2 11.8±3.9
Page 31 of 32 Oligo, oligomenorrhea; SA, secondary amenorrhea; Poly, polymenorrhea; NS, not significant; NA, not applicable. Other abbreviations are defined in Table 1. Significant differences in the post-hoc comparisons between patients with regular and irregular cycles: a, p<0.001; b, p<0.005; c, p<0.01; d, p<0.05
Page 32 of 32 Figure 1. Distribution of menstrual cycle pattern in the study population. 700 600 Number of patients 500 400 300 200 100 0 PA SA OM PM SA/OM SA/PM OM/PM RC/SA RC/OM RC/PM RC PA, primary amenorrhea; SA, secondary amenorrhea; OM, oligomenorrhea; PM, polymenorrhea; SA/OM, secondary amenorrhea alternating with oligomenorrhea; SA/PM, secondary amenorrhea alternating with polymenorrhea; OM/PM, oligomenorrhea alternating with polymenorrhea; RC, regular cycles; RC/SA, regular cycles alternating with secondary amenorrhea; RC/OM, regular cycles alternating with oligomenorrhea; RC/PM, regular cycles alternating with polymenorrhea.